Form 4: Rocket Pharmaceuticals Director Granted 30,000 Restricted Stock Units

Rocket Pharmaceuticals, Inc. Director Piratip Pratumsuwan was granted 30,000 restricted stock units, which will vest in full on June 18, 2026.

Summary

• Piratip Pratumsuwan, a Director of Rocket Pharmaceuticals, Inc. (RCKT), was granted 30,000 restricted stock units (RSUs).
• The transaction occurred on June 18, 2025.
• These RSUs convert to common stock on a one-for-one basis.
• The RSUs were granted at a price of $0 per unit.
• The RSUs will vest in full on June 18, 2026.
• Following this transaction, Piratip Pratumsuwan beneficially owns 30,000 common shares directly.

Sentiment

Score: 7

Explanation: The grant of restricted stock units to a director is a standard compensation practice that aligns the director's long-term interests with those of the shareholders, which is generally viewed positively for corporate governance and stability.

Positives

• The grant of restricted stock units to a director aligns the director's interests with those of shareholders, incentivizing long-term performance.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities, indicating a pre-planned compensation arrangement.

Future Outlook

The filing indicates a future vesting date of June 18, 2026, for the granted restricted stock units, implying a continued alignment of the director's interests with the company's long-term performance until at least that date.

Industry Context

The grant of restricted stock units to a director is a common practice in the biotechnology and pharmaceutical industries, as well as across publicly traded companies, to attract, retain, and incentivize key personnel by aligning their financial interests with shareholder value creation.

Comparison to Industry Standards

• The grant of restricted stock units (RSUs) as part of director compensation is a standard practice across various industries, including biotechnology. Companies like Moderna (MRNA) and BioNTech (BNTX) also utilize equity grants to compensate their directors and executives, aligning their interests with long-term company performance.
• The vesting schedule, with full vesting on a specific future date, is a common structure for such grants, similar to those observed in other biotech firms where long-term commitment is valued.
• The grant price of $0 for RSUs is typical, as these units represent a right to receive shares upon vesting, rather than a purchase.

Corporate Governance

Related Party Transactions

• The grant of 30,000 restricted stock units to Piratip Pratumsuwan, a Director of Rocket Pharmaceuticals, Inc., constitutes a related party transaction as it involves compensation to a member of the company's board. This is a standard form of compensation for directors.

Stakeholder Impact

• Shareholders: The grant of RSUs, upon vesting, will result in a minor dilution of existing shares, but it also aims to align the director's interests with long-term shareholder value creation.
• Director (Piratip Pratumsuwan): Receives equity compensation, aligning personal financial interests with the company's performance.

Next Steps

• The 30,000 restricted stock units are scheduled to vest in full on June 18, 2026.

Key Dates

Keywords

Rocket Pharmaceuticals, RCKT, Restricted Stock Units, RSU, Insider Transaction, Director Compensation, SEC Form 4, Equity Grant, Piratip Pratumsuwan